Abstract
References
- 1- Maraki S, Papadakis IS. Rothia mucilaginosa pneumonia: a literature review. Infect Dis (Lond) 2015; 47(3):125-129. 2. Collins MD, Hutson RA, Baveurd V, Falsen E. Characterization of a Rothia-like organism from a mouse: description of Rothia nasimurium sp. nov. and reclassification of Stomatococcus mucilaginosus as Rothia mucilaginosa comb. nov. Int J System Evolution Microbol 2000; 50:1247-1251. 3. Zhang F, He S, Jin J, Dong G, Wu H. Exploring salivary microbiota in AIDS patients with different periodontal stratuses using 454 GS-FLX Titanium pyrosequencing. Front. Cell Infect Microbiol 2015; 5(55):1-10. 4. Ramanan P, Barreto JN, Osmon DR, Tosh PK. Rothia bacteremia: a 10-year experience at Mayo Clinic, Rochester, Minnesota. J of Clin Microbiol 2014; 52(9):3184-3189. 5. Von Eiff, Herrmann M, Peters G. Antimicrobial susceptibilities of Stomatococcus mucilaginosus and of Micrococcus spp. Antimicrob Agen Chemother 1995; 39(1):268-270. 6. Bruminhent J, Tokarczyk MJ, Jungkind D, DeSimone JA. Rothia mucilaginosa prosthetic device infections: a case of prosthetic valve endocarditis. J Clin Microbiol 2013;51(5):1629-1632. 7. Abidi MZ, Ledeboer N, Banerjee A, Hari P. Morbidity and mortality attributable to Rothia bacteremia in neutropenic and nonneutropenic patients. Diagn Microbiol Infect Dis 2016; 85(1):116-120.
Rothia mucilaginosa Bacteremia Associated with HIV and Non-Hodgkin’s Lymphoma: A Case Report and Brief Review of Literature
Abstract
Rothia mucilaginosa is part of the normal flora of the oral cavity and is
typically is not associated with acute infection. However, growing evidence
suggests that Rothia mucilaginosa can be an opportunistic
pathogen in immunocompromised hosts. We present a case of Rothia bacteremia in
a patient with a compromised immune system due to human immunodeficiency virus
(HIV) and stage IV bulky diffuse large B cell lymphoma affecting the pharyngeal
space.
Keywords
Rothia mucilaginosa human immunodeficiency virus non-Hodgkin’s lymphoma bacteremia opportunistic infection case
References
- 1- Maraki S, Papadakis IS. Rothia mucilaginosa pneumonia: a literature review. Infect Dis (Lond) 2015; 47(3):125-129. 2. Collins MD, Hutson RA, Baveurd V, Falsen E. Characterization of a Rothia-like organism from a mouse: description of Rothia nasimurium sp. nov. and reclassification of Stomatococcus mucilaginosus as Rothia mucilaginosa comb. nov. Int J System Evolution Microbol 2000; 50:1247-1251. 3. Zhang F, He S, Jin J, Dong G, Wu H. Exploring salivary microbiota in AIDS patients with different periodontal stratuses using 454 GS-FLX Titanium pyrosequencing. Front. Cell Infect Microbiol 2015; 5(55):1-10. 4. Ramanan P, Barreto JN, Osmon DR, Tosh PK. Rothia bacteremia: a 10-year experience at Mayo Clinic, Rochester, Minnesota. J of Clin Microbiol 2014; 52(9):3184-3189. 5. Von Eiff, Herrmann M, Peters G. Antimicrobial susceptibilities of Stomatococcus mucilaginosus and of Micrococcus spp. Antimicrob Agen Chemother 1995; 39(1):268-270. 6. Bruminhent J, Tokarczyk MJ, Jungkind D, DeSimone JA. Rothia mucilaginosa prosthetic device infections: a case of prosthetic valve endocarditis. J Clin Microbiol 2013;51(5):1629-1632. 7. Abidi MZ, Ledeboer N, Banerjee A, Hari P. Morbidity and mortality attributable to Rothia bacteremia in neutropenic and nonneutropenic patients. Diagn Microbiol Infect Dis 2016; 85(1):116-120.
Details
| Journal Section | Case Report |
|---|---|
| Authors | |
| Publication Date | September 15, 2017 |
| DOI | https://doi.org/10.5799/jmid.367563 |
| IZ | https://izlik.org/JA56CF28UX |
| Published in Issue | Year 2017 Volume: 07 Issue: 03 |